Eupraxia Pharmaceuticals Inc.
EPRX
Rank in Stocks
#12213
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm... Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an extended-release anesthetic designed for extended post-operative pain relief. Furthermore, the company is actively developing product candidates for oncology applications. Established in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals Inc. was formerly known as Plaza Capital Partners Inc. until its renaming in May 2012.
Share Price
$7.41
Last synced: 2026-11-09
Market Cap
$489.42M
Change (1 day)
7.72%
Change (1 year)
11.90%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Eupraxia Pharmaceuticals Inc. (EPRX)
Category
Healthcare
EPS for Eupraxia Pharmaceuticals Inc. (EPRX)
EPS as of June 2026 TTM: $-1.02
According to Eupraxia Pharmaceuticals Inc.'s latest financial reports, its current EPS (TTM) is $-1.02. At the end of 2025 the company had an EPS of $-1.05, a decrease compared to its 2024 EPS of $-0.72.
EPS history for Eupraxia Pharmaceuticals Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.02 | -2.86% |
| 2025 | $-1.05 | 45.83% |
| 2024 | $-0.72 | -39.50% |
| 2023 | $-1.19 | 33.45% |
| 2022 | $-0.89 | -30.00% |
| 2021 | $-1.27 | 423.12% |
| 2020 | $-0.24 | -43.45% |
| 2019 | $-0.43 | -43.29% |
| 2018 | $-0.76 | 180.91% |
| 2017 | $-0.27 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,635.29% |
US
|
|
| $-7.07 | 593.14% |
US
|
|
| $-5.29 | 418.63% |
AU
|
|
| $12.88 | -1,362.75% |
BE
|
|
| $21.56 | -2,213.73% |
NL
|
Questions about Eupraxia Pharmaceuticals Inc.'s earnings per share (EPS)
What is Eupraxia Pharmaceuticals Inc.'s earnings per share (EPS)?
Eupraxia Pharmaceuticals Inc.'s earnings per share (EPS) over the last twelve months is $-1.02, as of Jun 2026.
What was Eupraxia Pharmaceuticals Inc.'s earnings per share (EPS) in 2025?
In 2025, Eupraxia Pharmaceuticals Inc.'s earnings per share (EPS) was $-1.05, compared with $-0.72 in 2024.
How has Eupraxia Pharmaceuticals Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Eupraxia Pharmaceuticals Inc.'s earnings per share (EPS) was highest in 2020 ($-0.24) and lowest in 2021 ($-1.27).
How does Eupraxia Pharmaceuticals Inc.'s earnings per share (EPS) compare with similar companies?
Eupraxia Pharmaceuticals Inc.'s earnings per share (EPS) ($-1.02) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.